Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers

Neuroscience Letters

Volumn 516, Issue 2, 2012, Pages 226-231

  Tan, Mengshan ^a,b   Wang, Shuying ^a,b   Song, Juexian ^a,b   Jia, Jianping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Key Neurodegenerative Laboratory of Ministry of Education   (China)

Author keywords

Alzheimer disease; Biomarkers; Cyclin dependent kinase inhibitor p21; Lymphocytes; Phosphorylation; Tumor suppressor protein p53

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P21; PROTEIN P53;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHOCYTES; MALE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860494301     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.03.093     Document Type: Article

References (25)

1. Bartolome F., Munoz U., Esteras N., Esteban J., Bermejo-Pareja F., Martin-Requero A. Distinct regulation of cell cycle and survival in lymphocytes from patients with Alzheimer's disease and amyotrophic lateral sclerosis. International Journal of Clinical and Experimental Pathology 2009, 2:390-398.
2. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003, 2:605-613.
3. Britschgi M., Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Archives of Neurology 2009, 66:161-165.
4. Carrillo M.C., Blackwell A., Hampel H., Lindborg J., Sperling R., Schenk D., Sevigny J.J., Ferris S., Bennett D.A., Craft S., Hsu T., Klunk W. Early risk assessment for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2009, 5:182-196.
5. Damjanac M., Page G., Ragot S., Laborie G., Gil R., Hugon J., Paccalin M.P.K.R. a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. Journal of Cellular and Molecular Medicine 2009, 13:1823-1832.
6. de las Cuevas N., Urcelay E., Hermida O.G., Saiz-Diaz R.A., Bermejo F., Ayuso M.S., Martin-Requero A. Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiology of Disease 2003, 13:254-263.
7. DeKosky S. Early intervention is key to successful management of Alzheimer disease. Alzheimer Disease and Associated Disorders 2003, 17(Suppl. 4):S99-S104.
8. Dezor M., Dorszewska J., Florczak J., Kempisty B., Jaroszewska-Kolecka J., Rozycka A., Polrolniczak A., Bugaj R., Jagodzinski P.P., Kozubski W. Expression of 8-oxoguanine DNA glycosylase 1 (OGG1) and the level of p53 and TNF-alphalpha proteins in peripheral lymphocytes of patients with Alzheimer's disease, Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Polish Academy of Sciences 2011, 49:123-131.
9. Dorszewska J., Florczak J., Rozycka A., Jaroszewska-Kolecka J., Trzeciak W.H., Kozubski W. Polymorphisms of the CHRNA4 gene encoding the alpha4 subunit of nicotinic acetylcholine receptor as related to the oxidative DNA damage and the level of apoptotic proteins in lymphocytes of the patients with Alzheimer's disease. DNA and Cell Biology 2005, 24:786-794.
10. Dotto G.P. p21(WAF1/Cip1): more than a break to the cell cycle?. Biochimica et biophysica acta 2000, 1471:M43-M56.
11. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology 2007, 6:734-746.
12. Facchetti M., Uberti D., Memo M., Missale C. Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. Molecular Endocrinology 2004, 18:162-172.
13. Golubnitschaja O. Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases. Amino Acids 2007, 32:359-371.
14. Hong L.Z., Zhao X.Y., Zhang H.L. p53-Mediated neuronal cell death in ischemic brain injury. Neuroscience Bulletin 2010, 26:232-240.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry 1992, 55:181-184.
16. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Molecular Cell 2005, 18:283-293.
17. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
18. Lim A.C., Qi R.Z. Cyclin-dependent kinases in neural development and degeneration. Journal of Alzheimer's disease: JAD 2003, 5:329-335.
19. Miyazaki H., Shiozaki A., Niisato N., Ohsawa R., Itoi H., Ueda Y., Otsuji E., Yamagishi H., Iwasaki Y., Nakano T., Nakahari T., Marunaka Y. Chloride ions control the G1/S cell-cycle checkpoint by regulating the expression of p21 through a p53-independent pathway in human gastric cancer cells. Biochemical and Biophysical Research Communications 2008, 366:506-512.
20. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., Moody D.M., O'Brien M.D., Yamaguchi T., Grafman J., Drayer B.P., Bennett D.A., Fisher M., Ogata J., Kokmen E., Bermejo F., Wolf P.A., Gorelick P.B., Bick K.L., Pajeau A.K., Bell M.A., DeCarli C., Culebras A., Korczyn A.D., Bogousslavsky J., Hartmann A., Scheinberg P. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
21. Rossig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Molecular and Cellular Biology 2001, 21:5644-5657.
22. Uberti D., Carsana T., Bernardi E., Rodella L., Grigolato P., Lanni C., Racchi M., Govoni S., Memo M. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. Journal of Cell Science 2002, 115:3131-3138.
23. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
24. Zhang G., Liu A., Zhou Y., San X., Jin T., Jin Y. Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. Journal of Ethnopharmacology 2008, 115:441-448.
25. Zhou X., Jia J. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neuroscience Letters 2010, 468:320-325.